



516 Rec'd PCT/PTO 02 AUG 1999

PCT
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Alex Jan van der Eb et al.

Serial No.: 08/973,560

Filed: December 5, 1997

For: p-53 BINDING PROTEIN CALLED
MDMX AND ENCODING SEQUENCES
FOR SAID PROTEIN

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 3839US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

July 28, 1999
Date of Deposit

Darlene Foucault
Signature of registered practitioner or other
person having reasonable basis to expect mailing
to occur on date of deposit shown pursuant to 37
C.F.R. § 1.8(a)(1)(ii)

Darlene Foucault
Typed/printed name of person whose signature is
contained above

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record. A Copy of the listed document is enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability



Attorney Docket: 3839US

as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Foreign Patent Documents

| <u>Document No.</u> | <u>Date</u> | <u>Country</u> |
|---------------------|-----------------|----------------|
| WO 97/00326 | January 3, 1997 | PCT |

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, applicant hereby identifies the following listed copending applications naming the same inventors:

Serial No.: 08/793,170
Filed: March 25, 1997
For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY

Serial No.: 09/333,820
Filed: June 15, 1999
For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY


Serial No.: 09/334,765
Filed: June 16, 1999
For: PACKAGING SYSTEMS FOR HUMAN RECOMBINANT ADENOVIRUS
TO BE USED IN GENE THERAPY

Serial No.: 09/298,745
Filed: April 23, 1999
For: MEANS AND METHODS FOR NUCLEIC ACID DELIVERY VEHICLE
DESIGN AND NUCLEIC ACID TRANSFER

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits in the above-identified application.

Respectfully submitted



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASK, BRITT & ROSSA
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: July 26, 1999

ACT/df

Enclosures: Form PTO-1449
Copy of documents cited

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE